Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic's (HOLX) Q2 revenues.

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2023 View Up

Hologic, Inc. (NASDAQ:HOLX ) Q2 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Ryan Simon - VP, IR Stephen MacMillan - Chairman, President and CEO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Tim Daley - Wells Fargo Casey Woodring - JPMorgan Anthony Petrone - Mizuho Group Elizabeth Garcia - UBS Andrew Cooper - Raymond James Jack Meehan - Nephron Research Puneet Souda - SVB Securities Jack Meehan - Nephron Research Max Masucci - Cowen & Company Tejas Savant - Morgan Stanley Andrew Brackmann - William Blair. John Murphy - Bank of America Vijay Kumar - Evercore ISI Navann Ty Dietschi - BNP Paribas Exane Operator Good afternoon, and welcome to the Hologic Second Quarter Fiscal 2023 Earnings Conference Call.

Hologic, Inc. (HOLX) Q2 2023 Results - Earnings Call Transcript

Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Hologic (HOLX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Hologic (HOLX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $2.07 per share a year ago.

Hologic (HOLX) Surpasses Q2 Earnings and Revenue Estimates

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #2QFY23--Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal second quarter ended April 1, 2023. “Hologic posted robust financial results in our second fiscal quarter, with both revenue and earnings exceeding our prior guidance,” said Steve MacMillan, the Company's chairman, president and chief executive officer. “Each of our core franchises grew double digits in the period, with consolidated organic growth of more than 20%, ex.

Hologic Announces Financial Results for Second Quarter of Fiscal 2023

Strong performance led by MyoSure and NovaSure is expected to have driven Hologic' s (HOLX) Q2 performance.

GYN Surgical Sales to Aid Hologic (HOLX) in Q2 Earnings

Hologic: A Superb Steward Of Capital, Offsets Top-Line Risks

Here is how Hologic (HOLX) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.

Is Hologic (HOLX) Outperforming Other Medical Stocks This Year?

AutoNation

Ryder System

Suzano S.A. - ADR

Valero Energy

AutoNation (AN), Suzano (SUZ), Valero Energy (VLO), Hologic (HOLX) and Ryder (R) are some of the stocks with high ROE to profit from as markets rise despite lower oil production.

Bet on 5 High ROE Stocks as Markets Shrug Off Oil Output Cut

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #2QFY23--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2023 on Monday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2023 on Monday, May 1, 2023

Hologic (HOLX) is currently well-positioned to achieve its full-year guidance of low double-digit organic growth ex-COVID in all three franchises, well above the 5-7% long-term growth rate.

Why You Should Add Hologic (HOLX) to Your Portfolio Now

Atkore International Group

AutoNation (AN), Atkore (ATKR), Valero (VLO), Hologic (HOLX) and Ryder (R) are some of the stocks with high ROE to profit from as markets brace for another rate hike.

Buy 5 High ROE Stocks as Markets Brace for 25 Bps Rate Hike

CNH Industrial NV

AutoNation (AN), CNH Industrial (CNHI), Valero (VLO), Hologic (HOLX) and Ryder (R) are some of the stocks with high ROE to profit from as equity markets decline in February.

Top 5 Stocks With High ROE as Equity Markets Flop in February

Hologic's (HOLX) GYN Surgical results underscore a more diverse surgical business with more growth drivers than in the past.

Hologic's (HOLX) Strategic Buyouts Aid, Surgical Arm Grows

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7 at 9:10 a.m. Eastern Time (E.T.) Cowen's 43rd Annual Health Care Conference is taking place March 6 - 8, 2023, at the Boston Marriott Copley Place in Boston, MA.

Hologic to Webcast Presentation at the Cowen 43rd Annual Health Care Conference

Hologic “Making a World of Difference” Through Global Sustainability Impact

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit unanimously affirmed a 2021 district court ruling that invalidated a Minerva patent asserted against Hologic. The appellate court ruled that Minerva's patent is invalid because it waited more than a year to file a patent application after showing a prototype of the invention at a trade show. “We are pleased with the U.S.

Court of Appeals Affirms District Court Decision Invalidating Minerva Surgical Patent

Thor Industries

THOR Industries (THO), CNH Industrial (CNHI), Valero Energy (VLO), Hologic (HOLX) and Suzano (SUZ) are some of the stocks with high ROE to profit from as inflation rises yet again.

5 Stocks With High ROE to Buy as Inflation Blows Hot Again

NovaSure® V5 Global Endometrial Ablation Device Approved for Use in Canada and Europe

Genmab - ADR

ServiceNow

Splunk

These top-ranked stocks are likely to beat on the bottom line in their next releases. These stocks include Genmab (GMAB), Hologic (HOLX), ServiceNow (NOW) and Splunk (SPLK).

4 Top Stocks to Buy on Earnings Beat Potential

Lower COVID-19 assays sales and supply chain challenges related to semiconductor chips dent Hologic's (HOLX) top line in Q1.

Hologic (HOLX) Q1 Earnings Beat Estimates, 2023 View Up

Hologic, Inc. (NASDAQ:HOLX ) Q1 2023 Earnings Conference Call February 1, 2023 4:30 PM ET Company Participants Ryan Simon - VP, IR Stephen MacMillan - Chairman, President and CEO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Max Masucci - Cowen & Company Puneet Souda - SVB Securities Vijay Kumar - Evercore ISI Tim Daley - Wells Fargo Tejas Savant - Morgan Stanley Derik de Bruin - Bank of America Dustin Scaringe - William Blair Navann Ty - BNP Paribas Exane Operator Good afternoon, and welcome to Hologic's First Quarter Fiscal 2023 Earnings Conference Call. My name is Justin, and I am your operator for today's call.

Hologic, Inc. (HOLX) Q1 2023 Earnings Call Transcript

Hologic (HOLX) delivered earnings and revenue surprises of 18.89% and 9.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Q1 Earnings and Revenues Beat Estimates

Hologic Inc. HOLX, +1.73% stock rose nearly 3% in the extended session Wednesday after the medical technology company reported quarterly earnings and sales that topped Wall Street views and raised its outlook for fiscal 2023. Hologic earned $187.4 million, or 75 cents a share, compared with $499.2 million, or $1.95 a share, in the year-ago period.

Hologic's fiscal Q1 tops views, company raises guidance for the year

MARLBOROUGH, Mass.--( BUSINESS WIRE )--Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal first quarter ended December 31, 2022.

News for Hologic Stock (HOLX)